Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InhaleRx Limited ( (AU:IRX) ) has provided an update.
InhaleRx Limited has commenced manufacturing its lead investigational product, IRX-211, for a Phase 2 clinical trial targeting breakthrough cancer pain, marking a significant operational milestone. The manufacturing is being conducted by Ab Initio Pharma, and this step signifies the company’s transition from development to clinical supply readiness, potentially offering a much-needed solution for patients and strengthening its market position.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical-stage drug development company focused on creating rapid onset inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The company is working on obtaining U.S. FDA approval for its products using efficient regulatory pathways, with a significant economic opportunity anticipated for shareholders.
Average Trading Volume: 317,166
Technical Sentiment Signal: Buy
Current Market Cap: A$7.9M
For an in-depth examination of IRX stock, go to TipRanks’ Overview page.